Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value
The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
Authors
- Mert Başaranoğlu (ORCID: https://orcid.org/0000-0002-9873-4920)
- Murat Bozlu (ORCID: https://orcid.org/0000-0002-8624-0149)
- Lülüfer Tamer (ORCID: https://orcid.org/0000-0002-0997-0260)
- Ali Nebioğlu (ORCID: https://orcid.org/0000-0001-6325-1534)
- Barış Saylam (ORCID: https://orcid.org/0000-0003-3256-8752)
- Rojda Tanrıverdi (ORCID: https://orcid.org/0000-0002-7004-790X)
- Erdem Akbay (ORCID: https://orcid.org/0000-0001-7669-414X)
- Semra Erdoğan (ORCID: https://orcid.org/0000-0003-2935-0760)
- Ercüment Ulusoy (ORCID: https://orcid.org/0000-0002-9385-128X)
Institutions
- Toros University (TR)
- Mersin Üniversitesi (TR)
Publication Details
- Journal
- BMC Urology
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s12894-024-01592-8
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Mersin Üniversitesi